Lijuan Xiang1,2, Sihan Wu1,3, Qingling Hua4, Chuyang Bao2, Hu Liu1. 1. Department of Tumor Biotherapy (5th Ward of the Department of Oncology), Anhui Provincial Cancer Hospital, West District of The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. 2. Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. 3. Department of Oncology, Affiliated Provincial Hospital of Anhui Medical University, Hefei, China. 4. Department of Oncology, Yijishan Hospital, Wannan Medical College, Wuhu, China.
Abstract
INTRODUCTION: Human exhaled volatile organic compounds (VOCs) are being extensively studied for the purposes of noninvasive cancer diagnoses. This article was primarily to assess the feasibility of utilizing exhaled VOCs analysis for gastrointestinal cancer (GIC) diagnosis. METHODS: PRISMA-based system searches were conducted for related studies of exhaled VOCs in GIC diagnosis based on predetermined criteria. Relevant articles on colorectal cancer and gastroesophageal cancer were summarized, and meta analysis was performed on articles providing sensitivity and specificity data. RESULTS: From 2,227 articles, 14 were found to meet inclusion criteria, six of which were on colorectal cancer (CRC) and eight on Gastroesophageal cancer(GEC). Five articles could provide specific data of sensitivity and specificity in GEC, which were used for meta-analysis. The pooled sensitivity, specificity, diagnostic odds ratio (DOR), and area under the curve (AUC) were calculated based on the combination of these data, and were 85.0% [95% confidence interval (CI): 79.0%-90.0%], 89.0% (95%CI: 86.0%-91.0%), 41.30 (21.56-79.10), and 0.93, respectively. CONCLUSION: VOCs can distinguish gastrointestinal cancers from other gastrointestinal diseases, opening up a new avenue for the diagnosis and identification of gastrointestinal cancers, and the analysis of VOCs in exhaled breath has potential clinical application in screening. VOCs are promising tumor biomarkers for GIC diagnosis. Furthermore, limitations like the heterogeneity of diagnostic VOCs between studies should be minded.
INTRODUCTION: Human exhaled volatile organic compounds (VOCs) are being extensively studied for the purposes of noninvasive cancer diagnoses. This article was primarily to assess the feasibility of utilizing exhaled VOCs analysis for gastrointestinal cancer (GIC) diagnosis. METHODS: PRISMA-based system searches were conducted for related studies of exhaled VOCs in GIC diagnosis based on predetermined criteria. Relevant articles on colorectal cancer and gastroesophageal cancer were summarized, and meta analysis was performed on articles providing sensitivity and specificity data. RESULTS: From 2,227 articles, 14 were found to meet inclusion criteria, six of which were on colorectal cancer (CRC) and eight on Gastroesophageal cancer(GEC). Five articles could provide specific data of sensitivity and specificity in GEC, which were used for meta-analysis. The pooled sensitivity, specificity, diagnostic odds ratio (DOR), and area under the curve (AUC) were calculated based on the combination of these data, and were 85.0% [95% confidence interval (CI): 79.0%-90.0%], 89.0% (95%CI: 86.0%-91.0%), 41.30 (21.56-79.10), and 0.93, respectively. CONCLUSION: VOCs can distinguish gastrointestinal cancers from other gastrointestinal diseases, opening up a new avenue for the diagnosis and identification of gastrointestinal cancers, and the analysis of VOCs in exhaled breath has potential clinical application in screening. VOCs are promising tumor biomarkers for GIC diagnosis. Furthermore, limitations like the heterogeneity of diagnostic VOCs between studies should be minded.
Authors: Sacheen Kumar; Juzheng Huang; Nima Abbassi-Ghadi; Patrik Španěl; David Smith; George B Hanna Journal: Anal Chem Date: 2013-05-29 Impact factor: 6.986
Authors: Michael Phillips; Renee N Cataneo; Christobel Saunders; Peter Hope; Peter Schmitt; James Wai Journal: J Breath Res Date: 2010-03-02 Impact factor: 3.262
Authors: Andras Bikov; Koralia Paschalaki; Ron Logan-Sinclair; Ildiko Horváth; Sergei A Kharitonov; Peter J Barnes; Omar S Usmani; Paolo Paredi Journal: BMC Pulm Med Date: 2013-07-09 Impact factor: 3.317
Authors: Z-q Xu; Y Y Broza; R Ionsecu; U Tisch; L Ding; H Liu; Q Song; Y-y Pan; F-x Xiong; K-s Gu; G-p Sun; Z-d Chen; M Leja; H Haick Journal: Br J Cancer Date: 2013-03-05 Impact factor: 7.640